$SGRY

Surgery Partners (SGRY) is set to report Q2 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts expect revenue of $846.97M and EPS of $0.06. The article cites insider selling only over the past six months, with 12 sales and no purchases, and notes mixed institutional 13F activity. Median analyst price target is $20.

Surgery Partners (SGRY) agreed to sell its interests in two Idaho Falls hospitals for about $795 million, while reaffirming 2026 revenue guidance of $3.35 billion to $3.45 billion. The article cites mixed stock performance and discusses a narrative fair value estimate of about $17.95 versus a $15.73 share price.

Surgery Partners (SGRY) said it will sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $795 million, valuing the facilities at roughly $1.15 billion, subject to physician partner approval. The company reaffirmed fiscal 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million.

Surgery Partners (NASDAQ:SGRY) rose 5.8% after agreeing to sell two Idaho Falls hospitals to Intermountain Health for about $1.15B. Surgery Partners expects about $795M for its ownership interests, with cash proceeds subject to purchase price adjustments. The deal needs approvals and regulatory steps and is expected to close in coming months. 2026 outlook was reaffirmed excluding the deal.

Surgery Partners (SGRY) said it signed agreements to sell its interests in Mountain View Hospital and Idaho Falls Community Hospital in Idaho to Intermountain Health for about $795 million. The hospitals were valued around $1.15 billion. Surgery Partners reaffirmed its FY2026 revenue of $3.35B to $3.45B and adjusted EBITDA of at least $530M excluding the deal. Shares rose to about $16.51.

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. sgry-20260721 0001638833 FALSE 07/21/2026 0001638833 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

Surgery Partners (SGRY) shares rose about 2.7% in the morning to around $17.15 after Cantor Fitzgerald reiterated an “Overweight” rating and set an $18.00 price target. Cantor cited some softness in Q2 ambulatory surgery center and outpatient nursing data, but kept a positive view. Other analysts expect profitability this year.

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. sgry-20260605 0001638833 FALSE 0001638833 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Surgery Partners (SGRY) shares fell 7.3% following its 2026 outlook, which included softer revenue guidance ($3.35B-$3.45B), despite reporting higher 2025 sales and launching a new $200 million share repurchase program. The company also appointed Lloyd Dean as an independent director while facing pressure from activist investor Ortelius Advisors. These developments intensify scrutiny on Surgery Partners' capital allocation, governance, and execution plans, especially given its ongoing net losses and significant debt.

Surgery Partners (SGRY) shares fell 12% following a Q4 EBITDA miss and weak guidance. This sell-off was driven by the market's reaction to the company's financial performance and future outlook. The article highlights investor concerns about Surgery Partners' immediate profitability and growth prospects.